It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.
Technology Appraisals Endorsement Process
The Department has reviewed its process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland. The new arrangements are detailed in following circulars, which is effective from 18th December 2013;
NICE Technology Appraisals – Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 02/13.
For information, details of the previous arrangement can be found on the following circular;
NICE Technology Appraisals and Clinical Guidelines – New Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 04/11
The following technology appraisals have been endorsed during 2020/21. Information on technology appraisals endorsed in previous years can be found on the homepage.
TA644 - Entrectinib for treating NTRK fusion-positive solid tumours
TA643 - Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer
TA642 - Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
TA641 - Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma
TA640 - Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant
TA639 - Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer
TA638 - Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
TA633 - Ustekinumab for treating moderately to severely active ulcerative colitis
TA632 - Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer
TA631 - Fremanezumab for preventing migraine
TA630 - Larotrectinib for treating NTRK fusion-positive solid tumours
NICE TA629 - Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab Note this guidance updates and replaces NICE Technology Appraisal TA472, which was endorsed by the DoH in January 2019.
NICE TA628 - Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer
NICE TA627 - Lenalidomide with rituximab for previously treated follicular lymphoma
NICE TA626 - Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure